Entries by Dana Fowlkes

June 18, 2018:

FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.

April 25, 2018:

FORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more

December 1, 2017:

FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.

November 28, 2017:

FORGE Life Science President & CEO, Lillian Chiang, presents “Targeting Host-cell Metabolism to Address Multiple Intracellular Pathogens” at the 2017 Chemical and Biological Defense Science & Technology Conference, Long Beach, CA. Read more

May 1, 2017:

FORGE Life Science secures a second in-kind services investment from BioArdis, LLC, expanding FORGE medicinal chemistry and DMPK research resources to include BioDuro, global provider of contract research services.

February 21, 2017:

FORGE Life Science Board of Directors meeting with new external members Richard J. Whitley, Brian Pusch, Steven Holtzman joining Founders Thomas E. Shenk and Lillian W. Chiang on the Board.

October 27, 2016:

FORGE Life Science Board Chairman, Thomas Shenk, presents at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.

October 20, 2016:

BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more.